Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M

Apellis Pharmaceuticals, Inc.

2023-Q2 EPS reported -$2.57 revenue$139,814,000

Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).
Net loss of $122.0M improved from $156.0M loss in Q2 2022; cash $616.3M.
SYFOVRE reduced nonsubfoveal GA lesion growth up to 45% at Months 24-30 in GALE extension.
Investigation of rare retinal vasculitis events found no drug product or manufacturing issues.
R&D expenses $95.7M, G&A $111.4M; company funded into Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apellis Pharmaceuticals, Inc. reported the second quarter 2023 results: revenue $95.0 million.

Period: the second quarter 2023
Revenue: $95.0 million
Result: reported results

Exact text from the filing

total revenue was $95.0 million for the second quarter of 2023, which consisted of $22.3 million of U.S. net product revenue of EMPAVELI, $67.3 million of U.S. net product revenue of SYFOVRE, and additional licensing and other revenue under the Sobi collaboration.

View on SEC.gov

Browse all earnings releases →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-198578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.